Novartis Ag (NVS) 104.28 $NVS
Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Teva-Active Biotech Start Phase II on MS Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:37PM CDT
Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech started patient enrollment in a phase II study on laquinimod for primary progressive multiple sclerosis.
MNK: 122.01 (-2.84), TEVA: 64.41 (+1.16), MNTA: 20.13 (+0.04), NVS: 104.28 (-1.22)
'Non-Cyclical Consumer Healthcare': How This Sector Will Create Long-Term Wealth
Peter Mantas - Seeking Alpha - Fri Apr 24, 1:39PM CDT
Allow me to provide you with a hypothetical portfolio containing only 5 stocks. This portfolio is somewhat diversified in that each company operates in different markets with different threats, competitors and opportunities, but all 5 companies have...
MCK: 229.20 (+0.09), AKRX: 55.24 (-0.68), PFE: 35.27 (-0.09), EW: 138.33 (-3.59), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), MOH: 63.85 (-0.13), ORCL: 43.08 (-0.31), CNC: 73.67 (+1.13), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), VRSK: 72.68 (+0.20), GILD: 103.69 (-1.52), RMD: 65.70 (-7.68), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), FICO: 93.85 (+0.55), WCN: 46.52 (+0.32), SRCL: 136.94 (-3.56), SNY: 51.75 (-0.01), ACN: 93.40 (-0.44), NVS: 104.28 (-1.22)
Biogen Q1 Misses Estimates As Tecfidera Stalls
at Investor's Business Daily - Fri Apr 24, 1:35PM CDT
Big-cap biotech Biogen (BIIB) missed Wall Street's Q1 estimates Friday as its multiple-sclerosis drug Tecfidera ran into unexpected headwinds, sending its stock down to a two-month low. Biogen's earnings excluding one-time items rose 55% over the...
BIIB: 401.71 (-28.57), NVS: 104.28 (-1.22)
French biotech's B-vitamin beats placebo in Phase 3 MS study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:57AM CDT
BIIB: 401.71 (-28.57), OPXA: 0.43 (-0.01), FWP: 32.03 (-0.06), RCPT: 169.88 (-1.26), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)
Novartis CEO Joseph Jimenez Nominated to GM Board
M2 - Fri Apr 24, 11:45AM CDT
General Motors Co. today announced the nomination of Novartis CEO Joseph Jimenez to its board of directors. GM also announced E. Neville Isdell will not stand for re-election at the company's Annual Meeting of Stockholders in June, pursuant to the board's retirement age policy.
GM: 35.59 (-0.33), NVS: 104.28 (-1.22)
Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:00AM CDT
Novartis' core earnings earnings per share came in at $1.33, down from $1.35 in the year-ago period but above the Zacks Consensus Estimate of $1.09.
SHPG: 255.11 (-0.26), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
8 Items Distorting The Net Income Of Prominent Companies
David Trainer - Seeking Alpha - Fri Apr 24, 8:30AM CDT
Filing season is now in the rear view mirror: The time of year when majority of publicly traded companies release their 10-K annual reports. During this time, we get a complete, audited view of a company's financials along with footnotes and the...
WBA: 85.98 (-0.71), JPM: 62.60 (-0.20), EBAY: 59.20 (+0.31), LBTYA: 52.85 (+0.47), BBRY: 10.38 (+0.11), DE: 88.39 (-0.20), GM: 35.59 (-0.33), GLW: 22.52 (-0.27), NVS: 104.28 (-1.22)
OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018
M2 - Fri Apr 24, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pk79vc/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018" report to their offering. Global Cushing's Syndrome Treatment Market Value Soaring to Almost $500 Million by 2018. The global Cushing's Syndrome (CS) treatment market will expand rapidly in value from approximately $179 million in 2013 to $499 million by 2018, representing an impressive Compound Annual Growth Rate (CAGR) of 22.74%. The report states that of the six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), the US was the largest contributor to CS treatment revenues in 2013, generating around $129 million. The US will see this figure rocket to $371 million by 2018, claiming a 74% share of the global market. Increasing disease prevalence will be a major driver behind the significant growth in the CS therapeutics arena, along with the arrivals of Novartis' Signifor LAR (pasireotide), a more convenient dosing regimen for Signifor, in the 6MM in 2018 and HRA Pharma's Ketoconazole HRA (ketoconazole) in Europe in 2015. Shaan Thakerar, MSc, Analyst covering Cardiovascular & Metabolic Disorders, says: Additionally, the US launch of second-generation steroidogenesis inhibitors, such as Cortendo AB's NormoCort (COR-003) and Novartis' LCI699, will also boost the market over the forecast period. These two drugs will be heralded by physicians and patients alike, as they will satisfy the high unmet need for safer and more effective products targeting CS, namely severe forms of the condition. Despite these various products' anticipated introductions into their respective markets,we believe that considerable opportunities remain for pharmaceutical and biotechnology companies to develop improved treatment options. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Oppportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/pk...ityanalyze
NVS: 104.28 (-1.22)
Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list
PR Newswire - Fri Apr 24, 5:15AM CDT
Novartis Pharmaceuticals Corporation (NPC) has been named the top company for diversity for the second year in a row on the annual DiversityInc Top 50 Companies for Diversity listing. DiversityInc announced the results of its 2015 Top 50 Companies for Diversity on April 23 at an awards ceremony in New York, NY. NPC also ranked second on the DiversityInc Top 10 Companies for Recruitment list and seventh on the Top 10 Companies for Employee Resource Groups list.
NVS: 104.28 (-1.22)
DiversityInc Unveils the 2015 Top 50 Companies for Diversity
PR Newswire - Fri Apr 24, 5:00AM CDT
Diversity and inclusion's keystone event in America took place at Cipriani Wall Street Thursday evening, as DiversityInc announced the 2015 Top 50 Companies for Diversity in front of more than 900 senior executives. Novartis Pharmaceuticals Corporation remained at the top of the rankings for their second year, while Kaiser Permanente jumped two spots to come in second. PricewaterhouseCoopers, EY, Sodexo, MasterCard Worldwide, AT&T, Prudential Financial, Johnson & Johnson, and Procter & Gamble rounded out the top 10. MassMutual Financial Group and Hilton Worldwide were both newcomers to the list this year.
NVS: 104.28 (-1.22)
Novartis AG (NVS) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Fri Apr 24, 3:12AM CDT
The following Novartis AG (NVS) conference call took place on April 23, 2015, 10:00 AM ET. This is a transcript of that earnings call:
NVS: 104.28 (-1.22)
Novartis EPS beats the Street
at Investor's Business Daily - Thu Apr 23, 5:33PM CDT
The drugmaking giant earned $1.29 a share in Q1, up 0.8% from a year earlier, beating views by 19 cents. Novartis' (NVS) net profit quadrupled to $13 bil due to gains on sales of units to Eli Lilly (LLY) and GlaxoSmithKline (GSK). Revenue fell 15% to...
LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Novartis's (NVS) CEO Joe Jimenez on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 23, 5:12PM CDT
NVS: 104.28 (-1.22)
AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed
at Investor's Business Daily - Thu Apr 23, 10:46AM CDT
Thursday morning brought a passel of earnings reports from large-cap drugmakers, which the market greeted with a mostly unenthusiastic response. One of the most anticipated reports came from AbbVie (ABBV), which unveiled its first full quarter with...
GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Ongoing Trial May Lead to Better Understanding of Oral Mucositis, a Debilitating Side Effect Affecting Many Cancer Patients
Marketwired - Thu Apr 23, 10:40AM CDT
An ongoing clinical trial at UCLA's Jonsson Comprehensive Cancer Center evaluating the use of an oral wound rinse for the management of oral mucositis/stomatitis, may pave the way for better understanding and prevention of the debilitating side effect seen in many patients undergoing chemotherapy and radiotherapy.
PTBI: 3.78 (+0.15), NVS: 104.28 (-1.22)
Novartis Q1 pharma sales off 9%; CF Ops up 27%; guidance maintained
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 6:37AM CDT
NVS: 104.28 (-1.22)
Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Teva-Active Biotech Start Phase II on MS Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:37PM CDT
Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech started patient enrollment in a phase II study on laquinimod for primary progressive multiple sclerosis.
MNK: 122.01 (-2.84), TEVA: 64.41 (+1.16), MNTA: 20.13 (+0.04), NVS: 104.28 (-1.22)
'Non-Cyclical Consumer Healthcare': How This Sector Will Create Long-Term Wealth
Peter Mantas - Seeking Alpha - Fri Apr 24, 1:39PM CDT
Allow me to provide you with a hypothetical portfolio containing only 5 stocks. This portfolio is somewhat diversified in that each company operates in different markets with different threats, competitors and opportunities, but all 5 companies have...
MCK: 229.20 (+0.09), AKRX: 55.24 (-0.68), PFE: 35.27 (-0.09), EW: 138.33 (-3.59), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), MOH: 63.85 (-0.13), ORCL: 43.08 (-0.31), CNC: 73.67 (+1.13), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), VRSK: 72.68 (+0.20), GILD: 103.69 (-1.52), RMD: 65.70 (-7.68), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), FICO: 93.85 (+0.55), WCN: 46.52 (+0.32), SRCL: 136.94 (-3.56), SNY: 51.75 (-0.01), ACN: 93.40 (-0.44), NVS: 104.28 (-1.22)
Biogen Q1 Misses Estimates As Tecfidera Stalls
at Investor's Business Daily - Fri Apr 24, 1:35PM CDT
Big-cap biotech Biogen (BIIB) missed Wall Street's Q1 estimates Friday as its multiple-sclerosis drug Tecfidera ran into unexpected headwinds, sending its stock down to a two-month low. Biogen's earnings excluding one-time items rose 55% over the...
BIIB: 401.71 (-28.57), NVS: 104.28 (-1.22)
French biotech's B-vitamin beats placebo in Phase 3 MS study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:57AM CDT
BIIB: 401.71 (-28.57), OPXA: 0.43 (-0.01), FWP: 32.03 (-0.06), RCPT: 169.88 (-1.26), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)
Novartis CEO Joseph Jimenez Nominated to GM Board
M2 - Fri Apr 24, 11:45AM CDT
General Motors Co. today announced the nomination of Novartis CEO Joseph Jimenez to its board of directors. GM also announced E. Neville Isdell will not stand for re-election at the company's Annual Meeting of Stockholders in June, pursuant to the board's retirement age policy.
GM: 35.59 (-0.33), NVS: 104.28 (-1.22)
Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:00AM CDT
Novartis' core earnings earnings per share came in at $1.33, down from $1.35 in the year-ago period but above the Zacks Consensus Estimate of $1.09.
SHPG: 255.11 (-0.26), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
8 Items Distorting The Net Income Of Prominent Companies
David Trainer - Seeking Alpha - Fri Apr 24, 8:30AM CDT
Filing season is now in the rear view mirror: The time of year when majority of publicly traded companies release their 10-K annual reports. During this time, we get a complete, audited view of a company's financials along with footnotes and the...
WBA: 85.98 (-0.71), JPM: 62.60 (-0.20), EBAY: 59.20 (+0.31), LBTYA: 52.85 (+0.47), BBRY: 10.38 (+0.11), DE: 88.39 (-0.20), GM: 35.59 (-0.33), GLW: 22.52 (-0.27), NVS: 104.28 (-1.22)
OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018
M2 - Fri Apr 24, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pk79vc/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018" report to their offering. Global Cushing's Syndrome Treatment Market Value Soaring to Almost $500 Million by 2018. The global Cushing's Syndrome (CS) treatment market will expand rapidly in value from approximately $179 million in 2013 to $499 million by 2018, representing an impressive Compound Annual Growth Rate (CAGR) of 22.74%. The report states that of the six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), the US was the largest contributor to CS treatment revenues in 2013, generating around $129 million. The US will see this figure rocket to $371 million by 2018, claiming a 74% share of the global market. Increasing disease prevalence will be a major driver behind the significant growth in the CS therapeutics arena, along with the arrivals of Novartis' Signifor LAR (pasireotide), a more convenient dosing regimen for Signifor, in the 6MM in 2018 and HRA Pharma's Ketoconazole HRA (ketoconazole) in Europe in 2015. Shaan Thakerar, MSc, Analyst covering Cardiovascular & Metabolic Disorders, says: Additionally, the US launch of second-generation steroidogenesis inhibitors, such as Cortendo AB's NormoCort (COR-003) and Novartis' LCI699, will also boost the market over the forecast period. These two drugs will be heralded by physicians and patients alike, as they will satisfy the high unmet need for safer and more effective products targeting CS, namely severe forms of the condition. Despite these various products' anticipated introductions into their respective markets,we believe that considerable opportunities remain for pharmaceutical and biotechnology companies to develop improved treatment options. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Oppportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/pk...ityanalyze
NVS: 104.28 (-1.22)
Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list
PR Newswire - Fri Apr 24, 5:15AM CDT
Novartis Pharmaceuticals Corporation (NPC) has been named the top company for diversity for the second year in a row on the annual DiversityInc Top 50 Companies for Diversity listing. DiversityInc announced the results of its 2015 Top 50 Companies for Diversity on April 23 at an awards ceremony in New York, NY. NPC also ranked second on the DiversityInc Top 10 Companies for Recruitment list and seventh on the Top 10 Companies for Employee Resource Groups list.
NVS: 104.28 (-1.22)
DiversityInc Unveils the 2015 Top 50 Companies for Diversity
PR Newswire - Fri Apr 24, 5:00AM CDT
Diversity and inclusion's keystone event in America took place at Cipriani Wall Street Thursday evening, as DiversityInc announced the 2015 Top 50 Companies for Diversity in front of more than 900 senior executives. Novartis Pharmaceuticals Corporation remained at the top of the rankings for their second year, while Kaiser Permanente jumped two spots to come in second. PricewaterhouseCoopers, EY, Sodexo, MasterCard Worldwide, AT&T, Prudential Financial, Johnson & Johnson, and Procter & Gamble rounded out the top 10. MassMutual Financial Group and Hilton Worldwide were both newcomers to the list this year.
NVS: 104.28 (-1.22)
Novartis AG (NVS) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Fri Apr 24, 3:12AM CDT
The following Novartis AG (NVS) conference call took place on April 23, 2015, 10:00 AM ET. This is a transcript of that earnings call:
NVS: 104.28 (-1.22)
Novartis EPS beats the Street
at Investor's Business Daily - Thu Apr 23, 5:33PM CDT
The drugmaking giant earned $1.29 a share in Q1, up 0.8% from a year earlier, beating views by 19 cents. Novartis' (NVS) net profit quadrupled to $13 bil due to gains on sales of units to Eli Lilly (LLY) and GlaxoSmithKline (GSK). Revenue fell 15% to...
LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Novartis's (NVS) CEO Joe Jimenez on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 23, 5:12PM CDT
NVS: 104.28 (-1.22)
AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed
at Investor's Business Daily - Thu Apr 23, 10:46AM CDT
Thursday morning brought a passel of earnings reports from large-cap drugmakers, which the market greeted with a mostly unenthusiastic response. One of the most anticipated reports came from AbbVie (ABBV), which unveiled its first full quarter with...
GILD: 103.69 (-1.52), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Ongoing Trial May Lead to Better Understanding of Oral Mucositis, a Debilitating Side Effect Affecting Many Cancer Patients
Marketwired - Thu Apr 23, 10:40AM CDT
An ongoing clinical trial at UCLA's Jonsson Comprehensive Cancer Center evaluating the use of an oral wound rinse for the management of oral mucositis/stomatitis, may pave the way for better understanding and prevention of the debilitating side effect seen in many patients undergoing chemotherapy and radiotherapy.
PTBI: 3.78 (+0.15), NVS: 104.28 (-1.22)
Novartis Q1 pharma sales off 9%; CF Ops up 27%; guidance maintained
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 6:37AM CDT
NVS: 104.28 (-1.22)
